Shire PLC (NASDAQ:SHPG) gapped up prior to trading on Thursday . The stock had previously closed at $196.14, but opened at $196.69. Shire PLC shares last traded at $198.17, with a volume of 396,623 shares changing hands.

Several equities research analysts have weighed in on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Shire PLC in a research note on Wednesday. Shore Capital reaffirmed a “buy” rating on shares of Shire PLC in a research note on Saturday, August 13th. TheStreet downgraded shares of Shire PLC to a “hold” rating in a research report on Thursday, August 4th. Zacks Investment Research raised shares of Shire PLC from a “sell” rating to a “hold” rating in a research report on Thursday, August 4th. Finally, RBC Capital Markets reissued an “outperform” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Four investment analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the company’s stock. Shire PLC presently has a consensus rating of “Buy” and an average price target of $237.41.

The firm has a 50-day moving average of $194.61 and a 200-day moving average of $178.46. The stock has a market cap of $45.48 billion and a PE ratio of 41.53.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.35. The firm had revenue of $2.43 million for the quarter, compared to analysts’ expectations of $2.28 billion. During the same quarter in the previous year, the company earned $2.63 EPS. The company’s quarterly revenue was up 55.9% compared to the same quarter last year. Equities analysts expect that Shire PLC will post $4.31 EPS for the current year.

Other large investors have recently bought and sold shares of the company. BlackRock Advisors LLC boosted its stake in Shire PLC by 11.3% in the fourth quarter. BlackRock Advisors LLC now owns 515,531 shares of the biopharmaceutical company’s stock worth $105,684,000 after buying an additional 52,220 shares during the last quarter. Advisors Asset Management Inc. boosted its stake in Shire PLC by 14.1% in the fourth quarter. Advisors Asset Management Inc. now owns 6,521 shares of the biopharmaceutical company’s stock worth $1,337,000 after buying an additional 805 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in Shire PLC by 50.4% in the fourth quarter. Bank of Montreal Can now owns 11,469 shares of the biopharmaceutical company’s stock worth $2,352,000 after buying an additional 3,841 shares during the last quarter.

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.